Introduction
Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia occurred in Wuhan, and rapidly spread throughout China. 1 Recent studies mainly focused on the epidemiological and clinical characteristics of patients with confirmed infection. [1] [2] [3] Little attention has been paid to the pancreatic injury caused by SARS-CoV-2 infection.
Methods
Fifty-two patients with COVID-19 pneumonia were admitted to Zhongnan Hospital of Wuhan University from January 20 th to February 28 th , 2020. The disease was confirmed by detecting SARS-CoV-2 nucleic acid in throat swab samples using the RT-PCR assay method. On admission, all patients had a comprehensive laboratory examination, including blood cytology, biochemistry and inflammatory indicators. Pancreatic injury was defined as any abnormality in amylase (normal range: 0~90 U/L) or lipase (0~70 U/L).
Serious illness was defined if satisfying at least one of the following items: (i) breathing rate ≥30/min; (ii) pulse oximeter oxygen saturation (SpO2) ≤93% at rest; (iii) ration of partial pressure of arterial oxygen (PaO2) to fraction of inspired oxygen (FiO2) ≤300mmHg (1mmHg=0.133kPa). During the hospitalization, each patient had a swab virus test every other day. Negative conversion time of SARS-CoV-2 was defined as the interval between symptom onset and the first of two consecutive negative virus tests.
Categorical data were described as percentages, and continuous data as mean with standard error (SD). Pearson correlation analysis was used to compare variables between the COVID-19 patients with and without pancreatic injury. A two-sided P<0.05 was considered statistically significant.
Results
Among the 52 patients with COVID-19 pneumonia, the incidence was 33% for heart injury (abnormal LDH or creatine kinase), 29% for liver injury (any abnormality in AST, ALT, GGT or ALP), 17% for pancreatic injury, 8% for renal injury (abnormal creatinine), and 2% for diarrhea. The nine patients with pancreatic injury had an average age of 55 years ranging from 25 to 71 (Table 1) . Five patients had underlying diseases such as hypertension, diabetes and heart disease. The most common chief complaints were fever and respiratory symptoms. Four patients were categorized into serious illness on admission. In laboratory tests, these patients were characterized by a decrease in lymphocytes and the subsets, and an increase in hepatic and myocardial enzymes and inflammatory indicators. Seven patients received corticosteroid therapy, and one with mechanical ventilation. The median time of SARS-CoV-2 negative conversion was 22 days from symptom onset.
Compared with the patients without pancreatic injury, those with pancreatic injury had a higher incidence of anorexia and diarrhea, severer illness on admission, lower level of CD3+ T-cell and CD4+ T-cell, higher level of AST, GGT, creatinine, LDH and ESR. Two groups showed no significant difference in corticosteroid treatment, mechanical ventilation or virus negative conversion time.
Discussion
In this study, we found that the incidence of pancreatic injury was not very low in the patients with COVID-19 pneumonia. In the previous SARS-CoV infected pneumonia (2003), the virus was detected not only in the tissues of lung, liver, kidney and intestine but also in pancreas, indicating pancreas as potential coronaviral targets. 4 Moreover, the SARS-CoV receptor of ACE2 was highly expressed in pancreas islets, and SARS-CoV infection caused the damage of islets and subsequent acute diabetes. 5 In our study of nine COVID-19 patients with pancreatic injury, six patients were found abnormal in blood glucose. These findings suggested the pancreatic injury in COVID-19 might be caused directly by the cytopathic effect mediated by local SARS-CoV-2 replication. On the other hand, the pancreatic injury might be caused indirectly by systemic responses to respiratory failure or the harmful immune response induced by SARS-CoV-2 infection, which also led to the damage in multiple organs. In this study, heart, liver and renal injuries were detected simultaneously. Third, most patients took antipyretics before admission, which could also cause drug-related pancreatic injury.
In conclusion, these results demonstrate potential mild pancreatic injury patterns in patients with COVID-19 pneumonia, and these may be related to direct viral involvement of the pancreas or from secondary enzyme abnormalities in the context of severe illness without substantial pancreatic injury. They do not demonstrate clinically severe pancreatitis as a common manifestation. Further research and larger series are warranted to evaluate whether a subset of patients have clinical pancreatitis as a presenting or concomitant disease entity. 
